Project Details
Description
Co-promotor van:
K.N. Gaarenstroom: onderzoek naar relatie HPV, anti-HPV en cytokeratinen in serum en weefsel en pogressie van CIN naar cervixcarcinoom (1990-1996). Promotiedatum: 16 januari 1997
M.J. Kagie: onderzoek naar de relatie tussen HPV, p-53 en progressie van VIN naar vulvacarci¬noom (1991-1996). Onderzoeksjaar KWF. ¬Promotiedatum: 16 juni 1997
A.M.F. Kersemaekers: Genetic alterations in carcinoma of the uterine cervix. Promotie¬datum: 14 oktober 1999
C.P. Maas: Late side effects of the surgical treatment of cervical and rectal carcinoma and the value of nerve sparing. Promotie¬datum: 23 oktober 2003
Promotor van:
S. Hazelbag: The role of cervical tumor cells in modulating local immune response. Promotie datum 2-2-2006
Q. Pieterse: Quality of life after treatment for cervical carcinoma and the effect of nerve sparing surgery. Promotie datum: 13-09-2007
M. van Poelgeest: The role of HPV-specific immunity in the development of cervical carcinoma and its impact on immunotherapeutic strategies. Promotie datum 10-10-2007
J. Kloth: Immune evasion of cervical carcinoma cells: down regulation of HLA-class I, loss of TNF-ά production and (over)production of TGF-beta. Promotie datum 2009
S. Piersma: Tumour-specific regulatory T-cells in cancer patients. 4 maart 2010
M. van den Hende: The role of HPV 16 peptide vaccination on the T cell response in HPV related disorders of the female genital tract. juni 2012
H. Zijlmans: The cytokine profile in cervical carcinoma. 13 jan 2014
P. de Vos van Steenwijk: The effect of HPV peptide vaccination on the local en systemic immune environment in HPV related disorders of the female genital tract. Gepland 2014
H.v. Meurs: Improving tretament strategies in ovarian cancer. Gepland 2014
P. Biewenga: prognostic models in carcinoma of the cervix; gepland 2014
S. Samuels: Immunosurveillance in HPV related cancers; gepland 2015-2016
H. van Meir: Farmacological aspects of chemo-immunotherapy. Gepland 2015 M.Rutten: predicting outcome in ovarian cancer treatment. Gepland 2015
I.van Luijk: Genomic profiling in cervical carcinoma: Gepland 2015
M.Derks: Morbidity or radicality in the treatment for carcinoma of the cervix. Gepland 2015
K.N. Gaarenstroom: onderzoek naar relatie HPV, anti-HPV en cytokeratinen in serum en weefsel en pogressie van CIN naar cervixcarcinoom (1990-1996). Promotiedatum: 16 januari 1997
M.J. Kagie: onderzoek naar de relatie tussen HPV, p-53 en progressie van VIN naar vulvacarci¬noom (1991-1996). Onderzoeksjaar KWF. ¬Promotiedatum: 16 juni 1997
A.M.F. Kersemaekers: Genetic alterations in carcinoma of the uterine cervix. Promotie¬datum: 14 oktober 1999
C.P. Maas: Late side effects of the surgical treatment of cervical and rectal carcinoma and the value of nerve sparing. Promotie¬datum: 23 oktober 2003
Promotor van:
S. Hazelbag: The role of cervical tumor cells in modulating local immune response. Promotie datum 2-2-2006
Q. Pieterse: Quality of life after treatment for cervical carcinoma and the effect of nerve sparing surgery. Promotie datum: 13-09-2007
M. van Poelgeest: The role of HPV-specific immunity in the development of cervical carcinoma and its impact on immunotherapeutic strategies. Promotie datum 10-10-2007
J. Kloth: Immune evasion of cervical carcinoma cells: down regulation of HLA-class I, loss of TNF-ά production and (over)production of TGF-beta. Promotie datum 2009
S. Piersma: Tumour-specific regulatory T-cells in cancer patients. 4 maart 2010
M. van den Hende: The role of HPV 16 peptide vaccination on the T cell response in HPV related disorders of the female genital tract. juni 2012
H. Zijlmans: The cytokine profile in cervical carcinoma. 13 jan 2014
P. de Vos van Steenwijk: The effect of HPV peptide vaccination on the local en systemic immune environment in HPV related disorders of the female genital tract. Gepland 2014
H.v. Meurs: Improving tretament strategies in ovarian cancer. Gepland 2014
P. Biewenga: prognostic models in carcinoma of the cervix; gepland 2014
S. Samuels: Immunosurveillance in HPV related cancers; gepland 2015-2016
H. van Meir: Farmacological aspects of chemo-immunotherapy. Gepland 2015 M.Rutten: predicting outcome in ovarian cancer treatment. Gepland 2015
I.van Luijk: Genomic profiling in cervical carcinoma: Gepland 2015
M.Derks: Morbidity or radicality in the treatment for carcinoma of the cervix. Gepland 2015
| Status | Active |
|---|---|
| Effective start/end date | 1/07/2010 → … |